NR4A1 and neoplasm: Molecules that specifically inhibit Nr4a1 and Nr4a2, but not Nr4a3, are also candidates for tumor Treg-specific inhibitors, as Foxp3CreNr4a-DcKO mice do not develop autoimmunity but the mice do develop augmented antitumor immunity.